Background: Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect. Methods: Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h. Results: No significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029). Conclusion: Elevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.
Bibliographical noteFunding Information:
This work was funded by the Movember Foundation. National Health and Medical Research Council Centre of Research Excellence (NHMRC-CRE; APP1116334) funded the additional materials involving serum analysis and cell work through Centre for Research Excellence in Prostate Cancer Survivorship. J-S.K is supported by the NHMRC Centre for Research Excellence in Prostate Cancer Survivorship Scholarship. Open Access funding enabled and organized by CAUL and its Member Institutions.
The authors thank Harry Perkins Institute, Nedlands, WA, Australia, for providing prostate cancer cell line DU145.
© 2022, The Author(s).
- Aged, 80 and over
- Body Composition
- Cell Proliferation
- Exercise Therapy
- Prostatic Neoplasms/pathology
- Prostatic Neoplasms, Castration-Resistant/therapy
PubMed: MeSH publication types
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't